Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation - PubMed (original) (raw)

Case Reports

Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation

J D Pirsch et al. Am J Med. 1989 Feb.

No abstract available

PubMed Disclaimer

Similar articles

• Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis.
  Kuo PC, Dafoe DC, Alfrey EJ, Sibley RK, Scandling JD. Kuo PC, et al. Transplantation. 1995 Jan 15;59(1):135-8. doi: 10.1097/00007890-199501150-00024. Transplantation. 1995. PMID: 7839414 No abstract available.
• Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
  Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG. Walker RC, et al. J Heart Lung Transplant. 1995 Mar-Apr;14(2):214-21. J Heart Lung Transplant. 1995. PMID: 7779838
• Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
  Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. Davis CL, et al. Clin Transplant. 1995 Feb;9(1):53-9. Clin Transplant. 1995. PMID: 7742583
• Epstein-Barr viral infection and posttransplantation lymphoproliferative disorders.
  Rustgi VK. Rustgi VK. Liver Transpl Surg. 1995 Sep;1(5 Suppl 1):100-8. Liver Transpl Surg. 1995. PMID: 9346606 Review. No abstract available.
• Pharmacotherapy of post-transplant viral infections.
  Sun HY, Singh N. Sun HY, et al. Expert Opin Pharmacother. 2008 Oct;9(14):2409-21. doi: 10.1517/14656566.9.14.2409. Expert Opin Pharmacother. 2008. PMID: 18778180 Review.

Cited by

• Anti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinase.
  Kira T, Grill SP, Dutschman GE, Lin JS, Qu F, Choi Y, Chu CK, Cheng YC. Kira T, et al. Antimicrob Agents Chemother. 2000 Dec;44(12):3278-84. doi: 10.1128/AAC.44.12.3278-3284.2000. Antimicrob Agents Chemother. 2000. PMID: 11083627 Free PMC article.
• The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.
  Robert A, Pujals A, Favre L, Debernardi J, Wiels J. Robert A, et al. Mol Oncol. 2020 Oct;14(10):2520-2532. doi: 10.1002/1878-0261.12759. Epub 2020 Aug 12. Mol Oncol. 2020. PMID: 32623836 Free PMC article.
• Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder.
  Tsai DE, Stadtmauer EA, Canaday DJ, Vaughn DJ. Tsai DE, et al. Med Oncol. 1998 Dec;15(4):279-81. doi: 10.1007/BF02787213. Med Oncol. 1998. PMID: 9951693
• The therapy of primary brain lymphoma.
  Hochberg FH, Loeffler JS, Prados M. Hochberg FH, et al. J Neurooncol. 1991 Jun;10(3):191-201. doi: 10.1007/BF00177531. J Neurooncol. 1991. PMID: 1895164 Review.
• Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
  Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Evens AM, et al. Curr Oncol Rep. 2010 Nov;12(6):383-94. doi: 10.1007/s11912-010-0132-1. Curr Oncol Rep. 2010. PMID: 20963522 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information